Advances in lymphoma maintenance therapy with rituximab / 中国肿瘤临床
Chinese Journal of Clinical Oncology
; (24): 1612-1615, 2014.
Article
in Zh
| WPRIM
| ID: wpr-457869
Responsible library:
WPRO
ABSTRACT
Rituximab is the first monoclonal antibody that has been approved for the treatment of lymphoma. Rituximab has shown significant efficacy in the treatment of B-cell non-Hodgkin's lymphomas, such as diffuse large B-cell and follicular lymphomas. Maintenance therapy with rituximab has further improved the prognosis in patients with follicular lymphoma. These patients responded to induction treatment. This antibody treatment has been recommended in treatment guidelines. The treatment strategy for lymphoma has continuously improved. Recent studies focused on how to improve the definition of the indication for maintenance therapy and how to optimize the current maintenance regimens. In this review, we summarized the main studies and the most recent advances on ritux-imab maintenance therapy in patients with lymphoma.
Full text:
1
Index:
WPRIM
Type of study:
Guideline
Language:
Zh
Journal:
Chinese Journal of Clinical Oncology
Year:
2014
Type:
Article